Ibrutinib, a Bruton's tyrosine kinase inhibitor, has become a standard treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The present pooled safety analysis of 4 randomized controlled studies demonstrated a favorable benefit/risk profile for ibrutinib in patients with CLL/SLL and mantle cell lymphoma. Background: Multiple studies have demonstrated the efficacy and safety of ibrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). This first-in-class inhibitor of Bruton's tyrosine kinase has become a standard treatment for patients with CLL and MCL. Patients and Methods: We conducted an integrated safety analysis to characterize the frequency, severity, natural history, and outcomes of adverse events (AEs) with ibrutinib versus comparators. Data were pooled from 4 completed randomized controlled studies that had included 756 ibrutinib-treated and 749 comparator-treated patients with CLL/SLL or relapsed/ refractory MCL. Safety analyses included reporting of AEs using crude and exposure-adjusted incidence rates. Results: The median treatment duration was 13.3 months (maximum, 28.2 months) for ibrutinib and 5.8 months (maximum, 27.3 months) for comparators. When adjusted for exposure, diarrhea, atrial fibrillation, and hypertension were the only common grade ! 3 AEs more often reported with ibrutinib than with the comparators. Dose reductions (7% vs. 14%) and discontinuation (12% vs. 16%) because of AEs occurred less often with ibrutinib, and deaths due to AEs occurred at similar rates (6% vs. 7%). When adjusted for exposure, the corresponding data were all lower with ibrutinib than with the comparators (0.06 vs. 0.22, 0.11 vs. 0.22, and 0.06 vs. 0.09 patient-exposure-years, respectively). The prevalence of common grade 3/4 AEs with ibrutinib generally decreased over time, with the exception of
Introduction
Ibrutinib, a first-in-class, once-daily inhibitor of Bruton's tyrosine kinase, has been approved by the US Food and Drug Administration for the treatment of patients with mantle cell lymphoma (MCL) who have received ! 1 prior therapy, patients with marginal zone lymphoma who require systemic therapy and have received ! 1 prior anti-CD20ebased therapy, and patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenström's macroglobulinemia, and chronic graft-versushost disease after failure of ! 1 lines of systemic therapy.
1 Although chemotherapy is given for a finite number of cycles, ibrutinib is continued until progressive disease or unacceptable toxicity, leading to prolonged ibrutinib exposure. The superiority of ibrutinib versus comparators has been reported in 4 phase III randomized controlled trials (RCTs) in patients with CLL/SLL or MCL (Supplemental Table 1 ; available in the online version). [2] [3] [4] [5] The results from each of these RCTs, including detailed safety information, have been previously reported. [2] [3] [4] [5] The aim of the present analysis was to expand on the previous findings and further characterize the adverse event (AE) profile of ibrutinib using safety data pooled across 4 RCTs involving previously untreated and relapsed/refractory patients who had received ! 1 therapy for CLL/ SLL or ! 1 rituximab-containing therapy for MCL. The pooling of these studies increased the sample size and allowed for the inclusion of a comparator group for comprehensive analysis of the incidence and outcomes of common AEs and AEs of clinical interest with ibrutinib.
Patients and Methods

Study Design and Patients
The methods for each study have been previously reported in detail. [2] [3] [4] [5] Briefly, RESONATE (PCYC-1112) included adult patients with CLL/SLL requiring treatment 6 who received ! 1 previous line of therapy. 2 RESONATE-2 (PCYC-1115) included patients aged ! 65 years with previously untreated CLL/SLL requiring treatment 6 (del[17p] excluded). 3 The HELIOS (CLL3001) included adult patients with CLL/SLL requiring treatment 6 (del[17p] excluded) who had received ! 1 previous line of systemic therapy. 4 The RAY study (MCL3001) included adult patients with MCL who had received ! 1 previous rituximabcontaining chemotherapy. 5 The cutoff dates for each study included in the present analysis were November 6, 2013, for RESONATE; January 12, 2015, for HELIOS; April 22, 2015, for RAY; and May 4, 2015 , for RESONATE-2. All studies were approved by the institutional review boards at each participating institution and conducted in accordance with the Declaration of Helsinki, and all patients provided written informed consent.
Randomization and Masking
In each of the RCTs, patients were randomly allocated 1:1 to the 2 treatment groups (additional information on randomization and masking has been provided in the Supplemental Appendix; available in the online version).
Procedures
In RESONATE, the patients were randomly assigned to oral ibrutinib versus intravenous (IV) ofatumumab. In RESONATE-2, patients were randomly assigned to oral ibrutinib versus oral chlorambucil. In HELIOS, all patients received IV bendamustine plus rituximab (BR) and were randomly assigned to oral ibrutinib or placebo starting on day 2 of cycle 1. In RAY, patients were randomly assigned to oral ibrutinib versus IV temsirolimus. In all 4 RCTs, crossover to the ibrutinib-containing arm was allowed after the development of progressive disease (PD; additional dosing information can be found in the Supplemental Appendix; available in the online version).
Statistical Analysis
Treatment-emergent AEs were examined using both crude (%) and exposure-adjusted incidence rates (EAIRs). EAIRs lend some perspective to comparisons between ibrutinib and comparators by accounting for differences in treatment duration or follow-up time between groups. The EAIR is defined as the number of patients with a specific event or group of events divided by the total exposure time among the patients in the treatment group at risk of an initial occurrence of the event. EAIRs are expressed in "patient-exposureyears" and as the difference (D) in EAIRs for ibrutinib versus comparators. Negative values for DEAIR indicate higher rates with comparators.
Results
In the present pooled analysis, 756 patients were treated with ibrutinib (469 as a single agent, 287 combined with BR), and 749 patients were treated with comparators (191 with ofatumumab, 132 with chlorambucil, 287 with placebo plus BR, 139 with temsirolimus). The baseline characteristics were similar between the 2 groups ( Table 1 ). The median follow-up was similar for the 2 groups (z16 months), although the median duration of study treatment was longer with ibrutinib (13.3 vs. 5.8 months; Table 2 ). Most patients continued receiving ibrutinib, with a low rate of treatment discontinuation compared with that reported for comparators (27% vs. 85%). The most common reason for discontinuation in both groups was PD ( Table 2 ). The baseline characteristics and patient disposition for the individual studies are shown in Supplemental Tables 2 and 3 ; available in the online version.
Common AEs
The 3 most common SOCs of AEs reported with both ibrutinib and comparators were infections, gastrointestinal disorders, and general disorders/administration-site conditions (Table 3) . Of the 22 most common AEs (! 10% of patients in either group based on individual preferred terms; Table 4), the rates of diarrhea, muscle spasms, and arthralgia were higher with ibrutinib than with the comparators when adjusted for exposure. The prevalence of the most common all-grade AEs with ibrutinib generally decreased over time, with the highest prevalence rates during months 0 to 3 (Supplemental Figure 1 ; available in the online version). The most common SOC of the AEs for the individual studies is shown in Supplemental Table 4 (available in the online version). The prevalence of all-grade AEs for the individual studies has been reported and was generally consistent with the findings of the present analysis.
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Grade 3/4 AEs
The 3 most common grade 3/4 AEs reported with ibrutinib and comparators were neutropenia, thrombocytopenia, and pneumonia (Table 5) . Of the 11 most common grade 3/4 AEs (! 3% of patients in either group), the rate of diarrhea, atrial fibrillation, and hypertension were higher with ibrutinib than with the comparators when adjusted for exposure. The prevalence of grade 3/4 AEs with ibrutinib generally decreased over time, with the highest prevalence rates for most common grade 3/4 AEs during months 0 to 3, except for hypertension, with a prevalence of w1% to 2% throughout the time periods examined, and neutropenic events, with a slightly higher prevalence during months 3 to 6 (Supplemental Figure 2 ; available in the online version). The most common grade 3/4 AEs from the individual studies have been previously reported, and the findings were generally consistent with those from the present analysis.
2-5
Serious AEs
The most common serious AEs (SAEs) reported with ibrutinib and comparators were pneumonia and febrile neutropenia in both groups and atrial fibrillation with ibrutinib and pyrexia with Safety Analysis of Ibrutinib in CLL/SLL and MCL comparators (Table 6 ). SAEs generally reflected AEs requiring hospitalization/causing prolongation of existing hospitalization, causing permanent impairment/requiring intervention to avoid permanent impairment, could be life-threatening, or result in death. Of the 6 most common SAEs (! 2% of patients in either group), only the rate of atrial fibrillation was higher with ibrutinib than with the comparators when adjusted for exposure. The most common SAEs for the individual studies are shown in Supplemental Table 5 (available in the online version).
Dose Reductions, Discontinuations, and Deaths From AEs
In accordance with the US prescribing information, for management of grade ! 3 nonhematologic toxicities, grade ! 3 neutropenia with infection or fever, or grade 4 hematologic toxicities, ibrutinib should be interrupted until the AE has recovered to grade 1 or baseline. For recurring events, dose reductions are recommended for the second and third occurrence, and discontinuation for the fourth occurrence (dose modification guidance provided in Supplemental Table 6 ; available in the online version). Dose reductions due to AEs were less frequent for the ibrutinib-treated patients than for the comparator-treated patients (7% [n ¼ 53] vs. 14% [n ¼ 107]; EAIR, 0.06 vs. 0.22). The most common AEs leading to dose reductions (> 3 in either group) were neutropenia (n ¼ 10) and diarrhea (n ¼ 5) in ibrutinib-treated patients. In comparator-treated patients, the most common AEs leading to dose reductions included hematologic toxicities (neutropenia
, and maculopapular rash (n ¼ 4).
Discontinuations due to AEs were also less frequent in ibrutinibtreated than in comparator-treated patients (12% [n ¼ 89] vs. 16% [n ¼ 120]; EAIR, 0.11 vs. 0.22). The most common AEs leading to discontinuations (> 3 in either group) were pneumonia (n ¼ 11), atrial fibrillation (n ¼ 6), neutropenia (n ¼ 5), and thrombocytopenia 
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(n ¼ 4) in ibrutinib-treated patients. In the comparator-treated patients, the most common AEs leading to discontinuations were
, and rash (n ¼ 4). Grade 1/2 AEs accounted for 2% (n ¼ 18) and 4% (n ¼ 32) of maximum-grade ibrutinib and comparator discontinuations, respectively. Deaths due to AEs were reported in 49 ibrutinib-treated patients (6%) and 49 comparator-treated patients (7%; EAIR, 0.06 vs. 0.09, respectively). The most common AEs leading to death (> 1 in either group) were sepsis (n
, and renal failure (n ¼ 2) in ibrutinib-treated patients. The most common AEs leading to death (> 1 in either group) were pneumonia (n ¼ 6), sepsis (n ¼ 4), CLL (n ¼ 4), septic shock (n ¼ 2), multiple organ dysfunction syndrome (n ¼ 2), and ischemic stroke (n ¼ 2) in the comparator-treated patients. Select safety topics of interest with ibrutinib were examined in detail for the pooled studies (Supplemental Table 7 ; available in the online version).
Hematologic Toxicities
Pooled hematologic toxicities were reported in 49% of ibrutinibtreated and 55% of comparator-treated patients (Supplemental Table 7 ; available in the online version). In ibrutinib-treated patients, the prevalence of hematologic toxicities was highest during months 0 to 3 (35%, all-grade; 23%, grade 3/4) and decreased over time. The median time to onset of the first hematologic toxicity was 1.0 month (median, 1.9 and 3.3 months to the first grade 3 and 4 event, respectively); 72% had complete resolution and 5% had partial improvement, with a median time from onset to resolution or improvement of 0.5 month. In the ibrutinib-treated patients, hematologic toxicities rarely led to discontinuation (n ¼ 9 [1%]; most commonly, neutropenia [n ¼ 5] and thrombocytopenia [n ¼ 4]) and did not result in death. In the comparator-treated patients, hematologic toxicities led to treatment discontinuation in 27 patients (4%; most commonly, neutropenia [n ¼ 15] and thrombocytopenia [n ¼ 10] ) and death for 1 patient (1%; febrile neutropenia).
The supportive measures for cytopenias in ibrutinib-and comparator-treated patients included growth factor support in 28% and 30%, red blood cell transfusions in 26% and 31%, immunoglobulin in 8% and 5%, and platelet transfusions in 6% and 8%, respectively. Among the ibrutinib-treated patients, most growth factor and blood support occurred in those treated with ibrutinib plus BR. In both groups, the mean platelet counts and hemoglobin levels increased over time, with a trend toward higher hemoglobin levels with ibrutinib throughout the study period evaluated. In comparator-treated patients, the mean neutrophil counts rapidly decreased by month 1 and did not improve to baseline levels through the last assessment (month 11). In the ibrutinib-treated patients, the mean neutrophil counts had decreased to less than the baseline levels beginning at month 3 but showed a trend toward returning to near baseline levels by month 11 (Supplemental Figure 3 ; available in the online version).
Infections
Infections were reported in 70% of ibrutinib-treated versus 63% of comparator-treated patients and were grade 3/4 in 23% versus 22%, respectively (Supplemental Table 7 ; available in the online version). In ibrutinib-treated patients, the prevalence of infections was highest during months 0 to 3 (41%, all-grade; 11%, grade 3/4) and generally decreased over time. The median time to the onset of first infection was 2.4 months (median, 3.5 and 3.7 months to the first grade 3 and 4 event, respectively); 76% had complete resolution, and 4% had partial improvement, with a median time from onset to resolution or improvement of 0.5 month. Despite prolonged treatment with ibrutinib, the rates of dose reductions (1% vs. 1%), discontinuation (4% vs. 3%), and death (2% vs. 3%) due to infection were similar with ibrutinib versus comparators (Supplemental Table 7 ; available in the online version).
Infections were further evaluated on a pathogen level, which showed that only mycobacterial infections occurred at a higher rate with ibrutinib than with comparators when adjusting for exposure (Supplemental Table 8 ; available in the online version). Hepatitis B virus reactivation occurred in 2 ibrutinib-treated patients (< 1%) and 3 comparator-treated patients (< 1%). Infections caused by atypical organisms were reported infrequently in both ibrutinib and comparator groups (Supplemental Table 8 ; available in the online version).
Diarrhea
Diarrhea was reported in 39% of ibrutinib-treated and 22% of comparator-treated patients. The prevalence of grade 3/4 diarrhea was uncommon (Supplemental Table 7 ; available in the online version). In the ibrutinib-treated patients, the prevalence of all-grade diarrhea was highest during 0 to 3 months (29%) and markedly decreased over time (Supplemental Figure 1 ; available in the online version). The median time to the onset of first diarrhea was 0.7 month; 83% had complete resolution, and < 1% had partial improvement, with a median time from onset to resolution or improvement of 0.2 month. Dose reductions and discontinuation because of diarrhea were rare with ibrutinib (1% and < 1%) and comparators (< 1% and < 1%).
Hypertension
Hypertension was more frequently reported in ibrutinib-treated patients than in the comparator group. Grade 3/4 hypertension was reported in 4% versus 1%, respectively (Supplemental Table 7 ; available in the online version). In the ibrutinib-treated patients, the prevalence of all-grade hypertension (1%-4%) and grade 3/4 hypertension (1%-2%) fluctuated over time ( Supplemental Figures 1  and 2 ; available in the online version). The median time to onset of first hypertension was 4.6 months; 38% had complete resolution and 1% had partial improvement, with a median time from onset to resolution of 0.4 month. Of 69 hypertension events that resolved or improved, 54 (78%) had resolved or improved after the patients had received medication for hypertension. No patient required a dose reduction for hypertension, and hypertension rarely resulted in discontinuation (n ¼ 1; < 1% ibrutinib-treated patients; and no comparator-treated patient).
Cardiac AEs
Cardiac disorders were reported in 15% of ibrutinib-treated and 10% of comparator-treated patients (Table 3 ). In the ibrutinibtreated patients, the most common cardiac AEs were reported under the MedDRA HLT "supraventricular arrhythmias" (Supplemental Table 9 ; available in the online version). Atrial fibrillation comprised most of these supraventricular arrhythmias. Atrial fibrillation was reported in 6% of ibrutinib-treated versus 2% of comparator-treated patients; grade 3/4 atrial fibrillation occurred in 3% versus < 1%, respectively (Supplemental Table 7 ; available in the online version). In ibrutinib-treated patients, the prevalence of atrial fibrillation was greatest during months 0 to 3 (3%, all grade; 2%, grade 3/4) and generally decreased over time (Supplemental Figure 1 ; available in the online version). However, atrial fibrillation was observed during months ! 18 (1%, all-grade; 1%, grade 3/4). The median time to the onset of first atrial fibrillation was 2.8 months; 69% had complete resolution and 4% had partial improvement, with a median time from onset to resolution or improvement of 0.1 month. Atrial fibrillation infrequently resulted in discontinuation in ibrutinib-treated patients (n ¼ 6 [1%] vs. no comparator-treated patient). No deaths or strokes resulted from atrial fibrillation.
Hepatobiliary Disorders
Hepatobiliary disorders were reported in 4% of ibrutinib-treated and 3% of comparator-treated patients (Supplemental Table 7 ; available in the online version). The median time to the onset of a first hepatobiliary disorder was 2.9 months; 59% had complete resolution, with a median time from onset to resolution of 0.5 month.
Grade 3/4 alanine transaminase, aspartate transaminase, and bilirubin (TBIL) increases were reported in 1% to 2% of patients in both groups. The grade 3/4 hepatobiliary AEs reported in > 1 ibrutinib-treated patients were hyperbilirubinemia (n ¼ 5), toxic hepatitis (n ¼ 2), and abnormal hepatic function (n ¼ 2). Hepatobiliary disorders did not result in discontinuation or death in the ibrutinib-treated patients (Supplemental Table 7 ; available in the online version). Graphs of liver function laboratory values (alanine transaminase, aspartate transaminase, and TBIL) over time for each of the 4 RCTs are shown in Supplemental Figure 4 (available in the online version). The findings with TBIL did not translate into clinically significant outcomes, with the reported hepatic events similar between the ibrutinib and comparator arms.
Bleeding Events
Grade 1/2 and 3/4 bleeding (pooled individual AEs) was reported in 35% and 3% of ibrutinib-treated patients and 15% and 2% of comparator-treated patients, respectively ( Table 7) . The most common types of bleeding with ibrutinib were contusion (8%), epistaxis (7%), petechiae (6%), and hematoma (5%) and were primarily low grade.
Major hemorrhage (any preferred term in the substandardized MedDRA, query hemorrhage terms [excluding laboratory terms] that was grade ! 3, serious, or any grade central nervous system hemorrhage/hematoma) was infrequent and occurred at similar frequencies in both groups, with no differences between groups when adjusted for exposure ( Table 7) . The most common events of major hemorrhage included epistaxis (n ¼ 2, ibrutinib; n ¼ 6 comparator), postprocedural hematoma (n ¼ 4, ibrutinib; n ¼ 1, Safety Analysis of Ibrutinib in CLL/SLL and MCL comparators), gastrointestinal hemorrhage (n ¼ 2, ibrutinib; n ¼ 3 comparators), subdural hematoma (n ¼ 4, ibrutinib), and vitreous hemorrhage (n ¼ 3, ibrutinib). In ibrutinib-treated patients, the prevalence of all-grade and grade 3/4 major hemorrhage remained stable over time (0.5%-2% for both all-grade and grade 3/4 events).
The median time to onset of first major hemorrhage was 5.7 months, and 83% had complete resolution with a median time from onset to resolution or improvement of 0.2 month. Major hemorrhage infrequently resulted in discontinuation (1%) or death (< 1%) in ibrutinib-treated patients (Supplemental Table 7 ; available in the online version). The results of a univariate Cox proportional hazards model showed that ibrutinib versus comparator treatment was not associated with major hemorrhage (P ¼ .6; hazard ratio, 1.1; 95% confidence interval [CI], 0.7-1.9) in this data set. Anticoagulant and antiplatelet agents were used during treatment for 22% and 39% of ibrutinib-treated patients and 19% and 37% of comparator-treated patients, respectively. The rate of major hemorrhage with anticoagulant and/or antiplatelet use compared with no use of either agent was 5% versus 4% with ibrutinib (relative risk, 1.4; 95% CI, 0.7-2.7) and 3% versus 3% with comparators (relative risk, 1.2; 95% CI, 0.5-2.8), respectively. The risk of major hemorrhage was not significantly increased with anticoagulant/antiplatelet use in either the ibrutinib or comparator groups.
Interstitial Lung Disease
ILD was reported in 2% of ibrutinib-treated and 3% of comparator-treated patients (Supplemental Table 7 ; available in the online version). In the ibrutinib-treated patients, the prevalence of ILD was < 1% during each period examined. The median time to onset of first ILD was 6.0 months, and 40% had complete resolution, with a median time from onset to resolution of 0.4 month. ILD resulted in discontinuation or death in 0 and 1 (< 1%) ibrutinib-treated patients, respectively (vs. 6 [1%; most often pneumonitis] and 0 comparator-treated patients, respectively).
Second Primary Malignancies
The rate of second primary malignancies in the ibrutinib-and comparator-treated patients was 6% versus 2% for nonmelanoma skin cancer (most commonly basal cell carcinoma or squamous cell carcinoma with ibrutinib [n ¼ 26 and n ¼ 18, respectively] and comparator [n ¼ 7 and n ¼ 9, respectively]), 2% versus 1% for non-skin cancer (most commonly prostate cancer or myelodysplastic syndromes with ibrutinib [n ¼ 3 and n ¼ 2, respectively] and comparator [both, n ¼ 2]), and < 1% each for melanoma (Supplemental Table 7 ; available in the online version).
Discussion
In the 4 RCTs, the superiority of ibrutinib versus the comparators was demonstrated in patients with CLL/SLL or MCL 2-5 and led to global approvals for these patient populations. Although AE data for each study have been reported separately, the present pooled analysis allowed for an in-depth assessment of the frequency and severity of common AEs and additional AEs of clinical interest. The most common AEs (! 20%) reported with ibrutinib were diarrhea, neutropenia, nausea, fatigue, pyrexia, anemia, and thrombocytopenia, all of which have been included in the ibrutinib prescribing information as common adverse reactions. 1 Although diarrhea was commonly reported with ibrutinib, it rarely resulted in ibrutinib discontinuation (< 1%), and most patients (83%) experienced complete resolution. The most common grade 3/4 AEs (! 5%) reported with ibrutinib were neutropenia, thrombocytopenia, pneumonia, febrile neutropenia, and anemia (the ibrutinib prescribing information also includes warnings and precautions for cytopenias and infections 1 ). Although cytopenias (hematologic toxicities) were common in both groups, when adjusting for treatment exposure, the rates of all-grade and grade 3/4 hematologic toxicities with the comparators were nearly double those with ibrutinib (DEAIR, À0.66 and À0.44, respectively). Most hematologic events began in the first month of treatment, and the mean platelet counts and hemoglobin levels increased over time in both groups. Most ibrutinib-treated patients with hematologic toxicities had complete resolution (72%) and discontinuation was rare (1%). During ibrutinib therapy, patients should be monitored for cytopenias by monthly assessments of the complete blood count.
Pneumonia was the only grade 3/4 infection that occurred in ! 3% in either group. When pooled, all-grade infections were commonly reported with both ibrutinib and comparators. When adjusting for treatment exposure, the rates of all-grade and grade 3/4 infections were lower with ibrutinib (DEAIR, À0.27 and À0.09, respectively). Hepatitis B virus reactivations have been reported in patients treated with ibrutinib, although our analysis showed that these events are rare (< 1%) in the clinical trial setting for both ibrutinib and comparator groups. Recent reports have focused on select cases of severe fungal infections in ibrutinib-treated patients. [7] [8] [9] In our analysis, severe fungal infections were rare, with a similar incidence of all fungal infections between ibrutinib and the comparators. Only mycobacterial infections were higher with ibrutinib when adjusting for exposure (DEAIR, < 0.01). In patients with an increased risk of opportunistic infections, prophylaxis should be considered according to standard institutional practices. Most ibrutinib-treated patients with infections had complete resolution. Despite prolonged treatment with ibrutinib, the rates of discontinuation (4% vs. 3%) or death (2% vs. 3%) due to infections were similarly low with ibrutinib compared with the comparators. Higher crude incidence rates and EAIRs were reported with ibrutinib than with comparators for grade 3/4 diarrhea (3% vs. 2%; DEAIR, < 0.01), atrial fibrillation (3% vs. 1%; DEAIR, 0.02), and hypertension (3% vs. 1%; DEAIR, 0.02). Atrial fibrillation and hypertension are also included in the ibrutinib prescribing information warnings and precautions.
1 It has been demonstrated in population-based studies that patients with cancer have an increased risk of atrial fibrillation compared with age-and gender-matched control cohorts. 10, 11 A retrospective analysis of a general cohort of patients with CLL showed that 6% of patients with newly diagnosed CLL had a history of atrial fibrillation and that another 6% without such a history developed atrial fibrillation during the subsequent follow-up period. 12 Although this previously published retrospective analysis included patients with CLL and did not include patients with MCL, it highlights the underlying risk of atrial fibrillation based on patient-and disease-related factors. The incidence of all-grade atrial fibrillation in the present analysis was reported more often in the ibrutinib-than in the comparator-treated
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Clinical Lymphoma, Myeloma & Leukemia October 2018 -655 patients (6% vs. 2%; DEAIR, 0.03). However, most ibrutinibtreated patients with atrial fibrillation had complete resolution, and discontinuation (1%) because of atrial fibrillation was uncommon. Reports have shown higher discontinuation rates (46%) in patients receiving ibrutinib; however, it is important to consider that more than one fourth of patients experiencing atrial fibrillation had a history of atrial fibrillation and risk factors for atrial fibrillation (eg, hypertension, valvular dysfunction, clinical congestive heart failure, angina, and recent infection). 13 A detailed analysis of atrial fibrillation from the 4 RCTs with ibrutinib has recently been reported and suggested that, in the clinical trial setting, atrial fibrillation was manageable with commonly used anticoagulant and/ or antiplatelet agents and without ibrutinib discontinuation for most patients with atrial fibrillation.
14 Patients treated with ibrutinib should be monitored clinically for atrial fibrillation, and electrocardiography should be performed for those who develop arrhythmic symptoms or new-onset dyspnea. Dose modifications in accordance with the US prescribing information guidelines should be considered for patients with persistent atrial fibrillation. Studies have shown that approximately one half of patients with CLL have hypertension at the time of CLL diagnosis, 15, 16 and management of hypertension is common for such patients. 17 In the present pooled analysis, the prevalence of all-grade and grade 3/4 hypertension in ibrutinib-treated patients fluctuated over time; 1 patient discontinued because of hypertension. However, approximately one third of patients experienced complete resolution. Patients should be monitored for new-onset hypertension or existing hypertension during ibrutinib therapy, and antihypertensive treatments should be initiated or adjusted, as appropriate, for individual patients. Hemorrhage has been cited as both a common adverse reaction and included in the warnings and precautions in the ibrutinib prescribing information.
1 In the present analysis, the incidence of any-grade bleeding was higher with ibrutinib than with comparator-treated patients. However, such an increase was only apparent with lowgrade bleeding events. Major hemorrhage was infrequent in both ibrutinib-and comparator-treated patients (4% vs. 3%). After adjusting for exposure, the rate of major hemorrhage was the same. A recent retrospective analysis of the Surveillance, Epidemiology, End ResultseMedicare database demonstrated that the risk of major hemorrhage for patients with CLL/SLL or MCL is z8 times higher than that in age-and gender-matched general population. 18 Most ibrutinib-treated patients who experienced major hemorrhage had complete resolution (83%), and discontinuation (1%) or death (< 1%) because of major hemorrhage was uncommon. When assessing the crude incidence rates, the association did not reach statistical significance between the concomitant use of anticoagulant and/or antiplatelet agents and an increased risk of major hemorrhage for either ibrutinib or the comparators. These findings are consistent with previous reports showing that major hemorrhage is infrequent in patients receiving concomitant anticoagulants and/or antiplatelet agents. 4, 19 Additionally, the risk of major hemorrhage was not different between patients receiving ibrutinib and those receiving a comparator on univariate analysis. 20 Patients receiving these agents during ibrutinib therapy should be monitored closely for signs of bleeding. In addition, withholding ibrutinib for ! 3 to 7 days before and after surgery should be considered, depending on the type of procedure and the potential risks of bleeding.
The potential limitations of the present analysis included pooling of studies across different disease states, doses, and treatment regimens, limiting the applicability of the data. Additionally, including the EAIR lends perspective to comparisons between groups by accounting for differences in drug exposure for ibrutinib versus comparators (median, 13.3 vs. 5.8 months) . However, it is limited in that it restricts the analysis to the first event and ignores the existence of later (multiple) events, because these cannot be assumed to have occurred independently of previous events. 21 Thus, the EAIR assumes the risk of an event occurring is constant over time, which might or might not have been the case for all events described.
Conclusion
Overall, the results from the present pooled safety analysis from 4 RCTs of ibrutinib in patients with CLL/SLL and MCL indicate a favorable safety profile compared with that of other standard treatments, despite prolonged ibrutinib therapy. Reported AEs with ibrutinib were primarily grade 1/2 and generally decreased in prevalence during the treatment course. With the exception of hypertension, the AEs of clinical interest resolved in most ibrutinibtreated patients with limited treatment discontinuations, dose reductions, or deaths from AEs.
Clinical Practice Points
Ibrutinib, a first-in-class inhibitor of Bruton's tyrosine kinase, has become a standard treatment for patients with CLL/SLL and MCL. The present comprehensive safety analysis comprising pooled data from 4 RCTs involving patients with CLL/SLL or relapsed/ refractory MCL has demonstrated a favorable safety profile for ibrutinib compared with that of other standard treatments, despite prolonged treatment. AEs with ibrutinib were primarily grade 1/2 and generally decreased in prevalence during the treatment course. Except for hypertension, the AEs of clinical interest resolved in most ibrutinib-treated patients, with limited treatment discontinuations, dose reductions, or deaths from AEs. (61) 117 (61) 135 (100) 132 (100) 143 (50) 127 (44) 86 (62) 85 (61) ! 75 43 (22) 36 (19) 46 (34) 47 (36) 40 (14) 36 (13) 29 (21) 33 (24) Male gender 129 (66) 132 (69) 88 (65) 80 (61) 191 (67) 188 (66) 100 (72) 106 (76) Race White 174 (89) 172 (90) 119 (88) 125 (95) 262 (91) 262 (91) 115 (83) 127 (91) Black 8 (4) 9 (5) 5 (4) 3 (2) 8 (3) 6 (2) 0 (0) 0 (0) Asian 3 (2) 2 (1) 9 (7) 3 (2) 1 (<1) 2 (1) 16 (12) 5 (4) Other 10 (5) 8 (4) 2 (1) 1 (1) 16 (6) 17 (6) 8 (6) 7 (5 ( Medical history of cardiac disorders 4 (2) 6 (3) 2 (1) 4 (3) 7 (2) 4 (1) 4 (3) 4 (3) ECOG PS 0-1 195 (100) 191 (100) 123 (91) 121 (92) 287 (100) 287 (100) 138 (99) 137 (99) > 1 0 (0) 0 (0) 12 (9) 11 (8) 
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